Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response”
We appreciate the interest generated by our manuscript,1 and thank Dr. Pol et al. for their letter,2 and the Editor for giving us the opportunity to respond.
Of the 28 million population of Punjab (2011 Census), 3.6% are estimated to be positive for anti HCV antibody and 2.6% (728,000) are estimated to test positive for HCV RNA.[1,2] A majority of these people may progress to cirrhosis and its complications including variceal bleeding, liver failure and hepatocellular carcinoma (HCC), or death.[3,4] Successful treatment of chronic hepatitis C (CHC) is associated with 62-84% reduction in all-cause mortality, 68-79% reduction in risk of HCC and 90% reduction in need for liver transplantation.
This is so far the first meta ‐analysis about TM6SF2 polymorphisms and chronic liver disease. Our pooled analyses suggested that rs58542926 polymorphism was significantly associated with chronic liver disease in both Asians and Caucasians. Future investigations are warranted to explore potential roles of other TM6SF2 polymorph isms in the development of chronic liver disease. AbstractBackgroundSome genetic association studies tried to investigate potential associations of transmembrane 6 superfamily member 2 (TM6SF2) polymorphisms with chronic liver disease. However, the results of these studies were not consistent. Thus...
ConclusionsApproximately 90% of US LI-RADS screening examinations were negative, 5% subthreshold, and 5% positive. Visualization scores were diagnostically acceptable in the vast majority (>95%) of examinations. US LI-RADS emphasized sensitivity and negative predictive value, which are key characteristics of a screening test.
Publication date: Available online 8 July 2019Source: Microbes and InfectionAuthor(s): Stanislas Pol, Sylvie LagayeSummaryThe infection with the hepatitis C virus (HCV) is an example of the translational research success. The reciprocal interactions between clinicians and scientists have allowed in 30 years the initiation of empirical treatments by interferon, the discovery of the virus, the development of serological and virological tools for diagnosis but also for prognosis (the non-invasive biochemical or morphological fibrosis tests, the predictors of the specific immune response including genetic IL28B polymorphisms)....
ConclusionPre-transplant performance status is one of the predictors of mortality after LDLT.
According to the World Health Organization, there are approximately 71 million people infected with Hepatitis C virus (HCV) worldwide and 1.75 million people are diagnosed each year. In the absence of antiviral treatment, HCV leads to cirrhosis, hepatocellular carcinoma (HCC), liver failure and death. Treatment with direct-acting antivirals (DAA) is highly efficacious and it has limited side effects. Current DAA combinations that are recommended as first-line treatment of HCV-infected patients by the AASLD-IDSA and EASL guidelines allow achieving sustained virological response (SVR) rates>90% for all HCV genotypes.
CONCLUSIONS: A thorough epidemiological investigation of the two first generations of this family, the study of their spouses and children, and the twenty years of follow up provided a strong presumption that the infection with HCV had occurred within this family through the promiscuous use of the same inadequately sterilized glass syringe for intramuscular therapies, as was a common practice during the fifties and sixties worldwide and still is in some part of the world. PMID: 31241295 [PubMed - in process]
CONCLUSIONS: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic. PMID: 31241282 [PubMed - in process]
CONCLUSIONS: The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity. The evidence on the effect of Radix Sophorae flavescentis on the proportion of participants with adverse events considered 'not to be serious' and on the proportion of participants with detectable HBV-DNA is still unclear. We advise caution regarding the results of Radix Sophorae flavescentis showing a reduction in the proportion of people with detectable HBeAg because the trials were at high risk of bias, because it is a non-validated...
CONCLUSION: SNP rs10945859 in the PARK2 gene could prove useful in predicting the clinical outcome in HCV-infected patients. PMID: 31208654 [PubMed]